MAX BioPharma is developing proprietary lipid based therapeutics for osteoporosis, localized bone growth (multiple applications) and pancreatic cancer.

Leveraging combined expertise in the fields of cellular biology, lipid biochemistry and drug discovery, MAX BioPharma is building a new generation of therapeutic agents that can address unmet medical needs with some of the most fatal and debilitating human disorders, like osteoporosis and pancreatic cancer. The company has developed a number of oxysterol small molecules that regulate normal physiology and disease and are excellent candidates for further therapeutic development.




  Graduated in 2018